PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

A case report of acute inferior myocardial infarction in a patient with severe hemophilia A after recombinant factor VIII infusion.

Abstract The extent of protective effects of hemophilia against thrombotic events such as myocardial infarction (MI) and other acute coronary syndromes remains to be determined, as major risk factors for cardiovascular disease exist despite factor VIII (FVIII) deficiency. We present a case report of a 41-year-old male with severe hemophilia A and several cardiovascular risk factors.
PMID
Related Publications

Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.

Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.

Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.

The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29384900
OWN - NLM
STAT- In-Process
LR  - 20180131
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 52
DP  - 2017 Dec
TI  - A case report of acute inferior myocardial infarction in a patient with severe
      hemophilia A after recombinant factor VIII infusion.
PG  - e9075
LID - 10.1097/MD.0000000000009075 [doi]
AB  - RATIONALE: The extent of protective effects of hemophilia against thrombotic
      events such as myocardial infarction (MI) and other acute coronary syndromes
      remains to be determined, as major risk factors for cardiovascular disease exist 
      despite factor VIII (FVIII) deficiency. We present a case report of a 41-year-old
      male with severe hemophilia A and several cardiovascular risk factors. PATIENT
      CONCERNS: This morbidly obese patient developed chest pressure, followed by chest
      pain and difficulty in breathing shortly after receiving on-demand treatment with
      intravenous recombinant FVIII (rFVIII) (turoctocog alfa) dosed per body weight.
      DIAGNOSES: An electrocardiogram revealed a diagnosis of inferior ST-segment
      elevation MI. INTERVENTIONS: The patient underwent an urgent coronary angiography
      using a radial artery approach. During the next 12 months, he received dual
      antiplatelet treatment, acetylsalicylic acid 100 mg, and clopidogrel 75 mg daily.
      His treatment for severe hemophilia A was changed to plasma-derived FVIII
      replacement therapy. OUTCOMES: During this 12-month period, he experienced
      several small bleeds in his elbows. CONCLUSIONS: The temporal relationship
      between rFVIII infusion and onset of the MI suggests a possible association;
      however, apart from obesity, the patient also had other major risk factors for
      arterial thrombosis, such as hypertension and smoking. Furthermore,
      atherosclerotic disease and underlying atherosclerotic changes could not be
      excluded with certainty. This case highlights the importance of studies assessing
      the impact of excess body weight on rFVIII dosing.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Zupancic-Salek, Silva
AU  - Zupancic-Salek S
AD  - Unit for Haemostasis, Thrombosis and Benign Diseases of Haematopoietic System,
      Division of Hematology, Department of Internal Medicine, University Hospital
      Centre Zagreb.
AD  - Medical School University of Zagreb, Zagreb.
AD  - Faculty of Medicine Osijek, J.J. Strossmayer University of Osijek, Osijek.
FAU - Vodanovic, Marijo
AU  - Vodanovic M
AD  - Unit for Haemostasis, Thrombosis and Benign Diseases of Haematopoietic System,
      Division of Hematology, Department of Internal Medicine, University Hospital
      Centre Zagreb.
FAU - Pulanic, Drazen
AU  - Pulanic D
AD  - Unit for Haemostasis, Thrombosis and Benign Diseases of Haematopoietic System,
      Division of Hematology, Department of Internal Medicine, University Hospital
      Centre Zagreb.
AD  - Medical School University of Zagreb, Zagreb.
AD  - Faculty of Medicine Osijek, J.J. Strossmayer University of Osijek, Osijek.
FAU - Skoric, Bosko
AU  - Skoric B
AD  - Medical School University of Zagreb, Zagreb.
AD  - Department of Cardiovascular Diseases, University Hospital Centre Zagreb, Zagreb,
      Croatia.
FAU - Matytsina, Irina
AU  - Matytsina I
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Klovaite, Jolanta
AU  - Klovaite J
AD  - Novo Nordisk A/S, Soborg, Denmark.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
EDAT- 2018/02/01 06:00
MHDA- 2018/02/01 06:00
CRDT- 2018/02/01 06:00
PHST- 2018/02/01 06:00 [entrez]
PHST- 2018/02/01 06:00 [pubmed]
PHST- 2018/02/01 06:00 [medline]
AID - 10.1097/MD.0000000000009075 [doi]
AID - 00005792-201712290-00008 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(52):e9075. doi: 10.1097/MD.0000000000009075.